Abstract
The recent failure of the T-cell-based HIV vaccine trial led by Merck & Co., Inc. prompts the urgent need to refocus on the question of which T-cell responses are required to control HIV replication. The well-described association between the expression of particular MHC class I molecules and successful containment of HIV or, in the macaque model, SIV replication provide a valuable starting point from which to evaluate more precisely what might constitute effective CD8(+) T-cell responses. Here, we review recent studies of T-cell-mediated control of HIV and SIV infection, and offer insight for the design of a successful T-cell-based HIV vaccine in the future.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
AIDS Vaccines / immunology*
-
Animals
-
CD8-Positive T-Lymphocytes / immunology*
-
CD8-Positive T-Lymphocytes / virology
-
HIV Infections / immunology*
-
HIV Infections / prevention & control
-
HIV Infections / virology
-
HIV-1 / immunology
-
HIV-1 / physiology*
-
Histocompatibility Antigens Class I / immunology*
-
Humans
-
Macaca mulatta
-
SAIDS Vaccines / immunology
-
Simian Acquired Immunodeficiency Syndrome / immunology
-
Simian Acquired Immunodeficiency Syndrome / prevention & control
-
Simian Acquired Immunodeficiency Syndrome / virology
-
Simian Immunodeficiency Virus / immunology
-
Simian Immunodeficiency Virus / physiology
-
Virus Replication / immunology*
Substances
-
AIDS Vaccines
-
Histocompatibility Antigens Class I
-
SAIDS Vaccines